Form 4: KalVista Pharmaceuticals Executive Trades RSUs

KalVista Pharmaceuticals Chief Development Officer Christopher Yea reported transactions involving restricted stock units and common stock.

Summary

• Christopher Yea, Chief Development Officer at KalVista Pharmaceuticals, Inc., engaged in transactions related to his equity compensation.
• On May 17, 2026, 1,774 Restricted Stock Units (RSUs) were settled, resulting in the acquisition of 1,774 shares of common stock.
• These RSUs represent a contingent right to receive one share of common stock upon settlement, with no cost to the executive.
• On May 18, 2026, 1,108 shares of common stock were sold at $26.76 per share.
• This sale was to cover tax withholding obligations arising from the vesting and settlement of RSUs, described as a 'sell to cover' transaction.
• Following these transactions, Yea beneficially owns 227,367 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as the transactions are routine for executive compensation and tax management, with no indication of significant insider buying or selling based on non-public information.

Positives

• The settlement of RSUs indicates the executive is receiving equity compensation as planned.
• The 'sell to cover' transaction for tax withholding is a standard and expected practice for executives receiving equity awards.

Negatives

• A portion of the executive's vested equity was sold, reducing direct holdings.

Risks

• The filing does not explicitly mention any risks associated with these transactions.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs.
• The sale was to satisfy tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

StockSavvy.ai notes that executive stock transactions, particularly those related to RSU settlements and tax withholding, are common within the pharmaceutical and biotechnology sectors as a standard part of compensation and liquidity management.

Stakeholder Impact

• Shareholders: The transactions do not indicate a change in the executive's overall beneficial ownership strategy, suggesting no immediate impact on share supply beyond the tax-related sale.

Next Steps

• Continued vesting of RSUs on a quarterly basis, with 1/16th of the total shares vesting each quarter, subject to continued service.

Key Dates

Keywords

KalVista Pharmaceuticals, Form 4, Christopher Yea, RSU settlement, Stock sale, Tax withholding, Beneficial ownership